On-Demand Therapy for Gastroesophageal Reflux Disease
暂无分享,去创建一个
D. Metz | J. Inadomi | P. Bytzer | C. Howden | S. V. Zanten
[1] P. Malfertheiner,et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] J. Dent,et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.
[3] G. Sachs,et al. Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.
[4] C. Howden,et al. Review article: immediate‐release proton‐pump inhibitor therapy – potential advantages , 2005, Alimentary pharmacology & therapeutics.
[5] E. Savarino,et al. Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group , 2005, The American Journal of Gastroenterology.
[6] T. Scholten,et al. On-Demand Therapy with Pantoprazole 20 mg as Effective Long-Term Management of Reflux Disease in Patients with Mild GERD: The ORION Trial , 2005, Digestion.
[7] L. Kupčinskas,et al. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease , 2005, European journal of gastroenterology & hepatology.
[8] E. Remák,et al. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK* , 2005, Current medical research and opinion.
[9] E. Toth,et al. Daily treatment with esomeprazole is superior to that taken on‐demand for maintenance of healed erosive oesophagitis , 2005, Alimentary pharmacology & therapeutics.
[10] R. Bagin,et al. Comparison of the effects of immediate‐release omeprazole powder for oral suspension and pantoprazole delayed‐release tablets on nocturnal acid breakthrough in patients with symptomatic gastro‐oesophageal reflux disease , 2005, Alimentary pharmacology & therapeutics.
[11] P. Wahlqvist,et al. Six‐month management of patients following treatment for gastroesophageal reflux disease symptoms – a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting , 2005, International journal of clinical practice.
[12] J. Zacny,et al. Systematic review: the efficacy of intermittent and on‐demand therapy with histamine H2‐receptor antagonists or proton pump inhibitors for gastro‐oesophageal reflux disease patients , 2005, Alimentary pharmacology & therapeutics.
[13] M. Fennerty,et al. Systematic review: is there excessive use of proton pump inhibitors in gastro‐oesophageal reflux disease? , 2004, Alimentary pharmacology & therapeutics.
[14] A. Blum,et al. Rationale and proposed algorithms for symptom‐based proton pump inhibitor therapy for gastro‐oesophageal reflux disease , 2004, Alimentary pharmacology & therapeutics.
[15] H. H. Juhl,et al. Costs and efficacy of three different esomeprazole treatment strategies for long‐term management of gastro‐oesophageal reflux symptoms in primary care , 2004, Alimentary pharmacology & therapeutics.
[16] A. Barkun,et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study , 2003, Alimentary pharmacology & therapeutics.
[17] B. Goldlust,et al. Comparative effects of an omeprazole antacid complex-immediate release (OAC-IR) and omeprazole-delayed release (OME-DR) on omeprazole pharmacokinetics (PK) and gastric pH in healthy subjects , 2003 .
[18] P. Bytzer. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients , 2003, American Journal of Gastroenterology.
[19] T. Lind,et al. Sufficient control of heartburn in endoscopy‐negative gastro‐oesophageal reflux disease trials , 2003, Scandinavian journal of gastroenterology.
[20] Clifford Goodman,et al. The burden of selected digestive diseases in the United States. , 2002, Gastroenterology.
[21] M. Simrén,et al. On-Demand Treatment in Patients with Oesophagitis and Reflux Symptoms: Comparison of Lansoprazole and Omeprazole , 2002, Scandinavian journal of gastroenterology.
[22] T. Levin,et al. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization , 2000, American Journal of Gastroenterology.
[23] John Hornberger,et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease , 2000, American Journal of Gastroenterology.
[24] L. Lachman,et al. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration , 2000, American Journal of Gastroenterology.
[25] A. Hungin,et al. Long-term prescribing of proton pump inhibitors in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.
[26] A. Hungin,et al. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.
[27] E. El-Omar,et al. Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers(Fig. 1) , 1999, American Journal of Gastroenterology.
[28] A. Blenkinsopp,et al. The rise and rise of proton pump inhibitor drugs: patients' perspectives. , 1997, Social science & medicine.
[29] R. Pounder,et al. Tolerance during 5 months of dosing with ranitidine, 150 mg nightly: a placebo-controlled, double-blind study. , 1991, Gastroenterology.
[30] R. Pounder,et al. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. , 1991, Gastroenterology.
[31] S. Sontag. The medical management of reflux esophagitis. Role of antacids and acid inhibition. , 1990, Gastroenterology clinics of North America.
[32] C. Wilder-Smith,et al. Tolerance to oral H2-receptor antagonists , 1990, Digestive Diseases and Sciences.
[33] C. Wilder-Smith,et al. Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients. , 1990, Gut.
[34] D. Johnston,et al. The effect of food on ranitidine‐induced inhibition of nocturnal gastric secretion , 1988, Alimentary pharmacology & therapeutics.
[35] R. Hunt,et al. Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist. , 1988, Gut.
[36] G. Sachs,et al. Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.
[37] R. Hunt,et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[38] J. Richter,et al. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. , 1997, The American journal of medicine.
[39] P. Reinikainen,et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. , 1997, The American journal of gastroenterology.
[40] A. Sandvik,et al. The intensity and variability of symptoms in dyspepsia. , 1993, Scandinavian journal of primary health care.
[41] R. Pounder,et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. , 1990, Alimentary pharmacology & therapeutics.
[42] R. Pounder,et al. Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. , 1990, Alimentary pharmacology & therapeutics.
[43] J. Misiewicz. Clinical relevance of tolerance to peptic ulcer healing and relapse. , 1990, Alimentary pharmacology & therapeutics.
[44] Misiewicz Jj. Clinical relevance of tolerance to peptic ulcer healing and relapse. , 1990 .